FDA Advisory Committees
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Advisory Committees
CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.
Mucodel has a oromucosal naloxone product in Phase I, and it wants US FDA to reconsider approval standards for intranasal products that are further along in development.
Drug review recommendations from FDA advisory panels, including regulatory actions. Updated weekly.
You must sign in to use this functionality.
Please Sign In
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with active subscriptions will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.